LEVAQUIN by Johnson & Johnson is [see microbiology(12. Approved for moderate, severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section, nosocomial pneumonia due to methicillinsusceptible staphylococcus aureus and 36 more indications. First approved in 1996.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
LEVAQUIN (levofloxacin) is a fluoroquinolone antibiotic administered via injection for moderate to severe bacterial infections. It treats nosocomial pneumonia, community-acquired pneumonia, acute bacterial sinusitis, skin/soft tissue infections, urinary tract infections, and chronic bacterial prostatitis across multiple gram-positive and gram-negative pathogens. The drug works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication.
Product approaching loss of exclusivity with minimal linked job postings, indicating consolidation phase and transition planning underway.
[see Microbiology(12.4)]. 12.3 Pharmacokinetics The mean ±SD pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following oral tablet, oral solution, or intravenous (IV) doses of levofloxacin are summarized in Table 8. Table 8: Mean ±SD Levofloxacin PK…
Worked on LEVAQUIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LEVAQUIN offers limited growth opportunity given LOE approaching lifecycle and zero active job postings linked to the product. Career roles focus on managing declining market share, defending reimbursement, and optimizing generic conversion strategies rather than expansion or innovation.